The US National Institutes of Health has fielded a lot of skepticism regarding the National Center for Advancing Translational Sciences. Many in the research and funding communities say drug discovery is best left to pharmaceutical and biotech companies and NIH should concentrate on its basic research mandate.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.